Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
convalescent plasma (Thomas Jefferson University)
- Development stage
- Unknown
- Lead developer
- Thomas Jefferson University
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Convalescent plasma (Thomas Jefferson University) is a biological therapy derived from the blood of individuals who have successfully recovered from COVID-19. This plasma contains a diverse pool of polyclonal antibodies, specifically those targeting the SARS-CoV-2 spike protein, which provide immediate passive immunity to the recipient. Thomas Jefferson University spearheaded research into this modality, including a Phase 2 open-label expanded access program (NCT04344938) aimed at treating hospitalized patients with severe or life-threatening COVID-19. The therapy works by neutralizing the SARS-CoV-2 virus, thereby preventing viral entry into host cells and potentially reducing the severity of the disease in patients who have not yet mounted an adequate endogenous immune response.
- Other names
- COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPconvalescent plasma
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)
Beyond the preview
Go deeper on convalescent plasma (Thomas Jefferson University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on convalescent plasma (Thomas Jefferson University).